comparemela.com

Ravik Amaravadi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Personalized mRNA Vaccines Could Significantly Reduce Risk of Melanoma Relapse

Moderna and Merck recently finished a phase 2 trial for personalized mRNA vaccines for melanoma patients. The vaccine uses genetic material from a person’s tumor to develop a vaccine that teaches a person’s immune system to identify cells that match that tumor, attacking those cells before they have a chance to grow.

Research at Penn Medicine Led by Indian American Prof Ravi Amaravadi Receives $11 7 M National Cancer Institute Grant

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.